Literature DB >> 19342944

Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.

Emanuela Veras1, Tsui-Lien Mao, Ayse Ayhan, Stefanie Ueda, Hong Lai, Mutlu Hayran, Ie-Ming Shih, Robert J Kurman.   

Abstract

Ovarian clear cell carcinomas (CCC) typically present as large adnexal, stage I tumors and are generally considered highly malignant. They are frequently associated with endometriosis and, less often with clear cell adenofibromas. We hypothesized that CCCs are a heterogeneous group of tumors, some arising from a cyst and others from an adenofibroma. To test this hypothesis, 122 cases of CCC were retrieved from the surgical pathology files of National Taiwan University Hospital (74), The Johns Hopkins Hospital (23), and Serei Mikatahara General Hospital (23) (1985 to 2006). Cases were divided into 3 subgroups: (1) cystic, (2) adenofibromatous, and (3) indeterminate. Various features were analyzed including: age, race, laterality, tumor size, architectural pattern (papillary, tubulo-cystic, solid, mixed patterns), grade, mitotic index, association with endometriosis including atypical endometriosis/intraepithelial carcinoma, stage and survival. Nearly 70% of all the patients were diagnosed as stage I. The 2-year and 5-year survival (all stages) was 78% and 68%, respectively. Striking clinicopathologic differences were observed between cystic and adenofibromatous CCCs. Cystic CCC was more frequently diagnosed as stage I compared with adenofibromatous CCC (75% vs. 44%). Conversely, adenofibromatous CCCs were diagnosed more often in advanced stages (stages II-IV) compared with cystic CCCs (56% vs. 18%). Both the cystic and adenofibromatous CCC forms were associated with endometriosis and atypical endometriosis/intraepithelial carcinoma, but the frequency was much higher in the cystic group. Specifically, endometriosis was found in 91% of cystic CCCs and atypical endometriosis/intraepithelial carcinoma in 62% of these cases, whereas endometriosis was found in 44% of adenofibromatous CCCs and atypical endometriosis/intraepithelial carcinoma in 11% of cases. A predominantly papillary pattern was seen in 47% of cystic CCCs, whereas none of the adenofibromatous carcinomas displayed a predominantly papillary pattern. A more favorable outcome was observed for cystic CCCs compared with adenofibromatous CCCs (all stages) which was accounted for by the high proportion of stage I tumors. The 2-year and 5-year survival for the cystic CCCs was 82% and 77% and for the adenofibromatous CCCs (all stages), 62% and 37%, respectively. In summary, subdividing ovarian CCCs into cystic and adenofibromatous CCC reveals differences in a number of clinicopathologic features including their association with endometriosis, histologic patterns, stage distribution, and clinical behavior. Because there were a relatively small number of adenofibromatous CCCs in this series, additional cases must be studied to confirm these findings.

Entities:  

Mesh:

Year:  2009        PMID: 19342944     DOI: 10.1097/PAS.0b013e31819c4271

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  31 in total

1.  Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.

Authors:  Yuji Matsuo; Hironori Tashiro; Hiroyuki Yanai; Takuya Moriya; Hidetaka Katabuchi
Journal:  Med Mol Morphol       Date:  2014-11-15       Impact factor: 2.309

2.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.

Authors:  Elisabetta Kuhn; Alan K Meeker; Kala Visvanathan; Amy L Gross; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

3.  Major clinical research advances in gynecologic cancer in 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Kidong Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

4.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

5.  ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin.

Authors:  Changshuai Lyu; Yinglan Zhang; Xingnan Zhou; Jinghe Lang
Journal:  Exp Ther Med       Date:  2016-11-02       Impact factor: 2.447

6.  Transcriptional upregulation of HNF-1β by NF-κB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression.

Authors:  Erina Suzuki; Sabine Kajita; Hiroyuki Takahashi; Toshihide Matsumoto; Tomoko Tsuruta; Makoto Saegusa
Journal:  Lab Invest       Date:  2015-06-01       Impact factor: 5.662

Review 7.  Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.

Authors:  Daichi Maeda; Ie-Ming Shih
Journal:  Adv Anat Pathol       Date:  2013-01       Impact factor: 3.875

8.  Primary Ovarian Clear Cell Adenofibroma of Borderline Malignancy.

Authors:  Ebru Cakir; Engin Aydin; Nılufer Imamoglu Durmus; Emine Samdanci; Nurhan Sahin; Zeynep Nurkabul
Journal:  Oman Med J       Date:  2012-01

9.  Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Authors:  Masafumi Kato; Masashi Takano; Morikazu Miyamoto; Naoki Sasaki; Tomoko Goto; Ayako Suzuki; Junko Hirata; Hidenori Sasa; Hitoshi Tsuda; Kenichi Furuya
Journal:  Mol Clin Oncol       Date:  2016-08-02

Review 10.  [Endometriosis-related ovarian tumors].

Authors:  D Schmidt; U Ulrich
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.